Beyond Azacitidine: Investigating new therapeutic strategies for the treatment of MDS
Dr Ashwin Unnikrishnan, University of NSW (Sydney).
Funding period: 2019-2022.
Myelodysplastic Syndrome (MDS) is one of the most common haematological malignancies in developed societies with ageing populations, including in Australia. MDS is characterised by impaired peripheral blood cell production and abnormal blood cells in the bone marrow. The drug azacitidine (AZA) is currently the best available treatment for myelodysplastic syndrome (MDS), yet only approximately half of treated patients respond to the drug, and others eventually suffer relapse. There is an important and urgent clinical need for developing better therapeutic options beyond AZA in MDS.
Dr Unnikrishnan will investigate mechanisms by which azacitidine inhibits MDS cells and identify cellular pathways and features that are modulated by azacitidine treatment. This study will provide insight into why some patients do not respond and lay the groundwork for development of alternative therapeutic strategies.Posted on December 18th, 2019
Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.